A clinical trial assessing neuropsychotherapeutics in alcohol use disorder
Latest Information Update: 20 Sep 2022
At a glance
- Drugs EPV 001 (Primary)
- Indications Alcoholism
- Focus Adverse reactions
- 20 Sep 2022 New trial record
- 13 Sep 2022 According to EpiVario, Inc., media release, company to receive over $250,000 in research funding, this funding will advance the preclinical research and aspire to begin this human trial by the first half of 2024.